The FDA has?lifted?the partial clinical hold it placed on a phase 1 trial of Mersana Therapeutics’ HER2-targeted antibody-drug conjugate (ADC). Regulatory officials put enrollment in the XMT-1522?breast cancer trial on hold in July after learning of the d